TMDX - TransMedics Group, Inc.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Emerald Investment Advisers LLC bought a new stake in shares of TransMedics Group, Inc. (NASDAQ: TMDX) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 30,456 shares of the company's stock, valued at approximately $2,023,000. Emerald Investment Advisers LLC owned approximately 0.09%
NEW YORK, Aug. 21, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.
Moderna jumped 177% on a cancer-vaccine first, plus retail's reversal
New York, New York--(Newsfile Corp. - August 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.
NEW YORK, Aug. 18, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.
GOOG buys data to aid AI models, Tesla gets closer to formal Cybercab launch, and more
TransMedics Group NASDAQ: TMDX outlined its growth strategy at Canaccord Genuity's 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology and broader adoption in heart and lung transplantation.
NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ), announces that K
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) (“TransMedics” or the “Company”). TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System,.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
A Deep Dive into the Small-Cap Pioneer's Latest Moves, Including a -0.42% Impact from Exiting a Major StakeCharles M. Royce, a pioneer of small-cap investing an
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.
NEW YORK, Aug. 08, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).
On August 06, 2026, TransMedics Group Inc (TMDX) shares rose 4.9%, bringing the current price to $80.21. The stock has fluctuated within a 52-week range of $60.
TransMedics Group, Inc. (NASDAQ: TMDX - Get Free Report) shares gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $80.75, but opened at $72.34. TransMedics Group shares last traded at $74.30, with a volume of 847,115 shares traded. The company reported $0.44 earnings
NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.
TMDX's Q2 revenue beat and raised outlook are overshadowed by earnings miss, declining margins and sharply higher operating costs.